Lindsey Rolfe - Sep 1, 2022 Form 4 Insider Report for Clovis Oncology, Inc. (CLVS)

Role: Officer
Signature: /s/ Lindsey Rolfe
Stock symbol: CLVS
Transactions as of: Sep 1, 2022
Transactions value $: -$3,054
Form type: 4
Date filed: 9/6/2022, 04:15 PM
Previous filing: Aug 3, 2022
Next filing: Nov 3, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CLVS	Common Stock	Options Exercise		+5.06K	+4.73%		112K	Sep 1, 2022	Direct	F1
transaction	CLVS	Common Stock	Sale	-$3.05K	-2.55K	-2.27%	$1.20^*	110K	Sep 2, 2022	Direct	F2

Showing 1 to 2 of 2 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CLVS	Restricted Stock Units	Options Exercise	$0	+5.06K	+11.11%	$0.00	50.6K	Sep 1, 2022	Common Stock	5.06K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2	Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3	On March 1, 2021, the reporting person was granted 81,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2022, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date

Remarks:

Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance